Literature DB >> 15488030

Absence of neuronal nitric oxide synthase (nNOS) as a pathological marker for the diagnosis of Becker muscular dystrophy with rod domain deletions.

S Torelli1, S C Brown, C Jimenez-Mallebrera, L Feng, F Muntoni, C A Sewry.   

Abstract

Immunohistochemistry using antibodies to dystrophin is the pathological basis for the diagnosis of Duchenne and Becker muscular dystrophy (DMD and BMD). While the sarcolemma of DMD muscle is negative, BMD muscle generally shows variable labelling because of the translation of a partially functional dystrophin that is localized to the sarcolemma. In rare cases, however, this labelling is equivocal and similar to that observed in controls making diagnosis difficult. We report here that in such instances immunolabelling with antibodies to the neuronal form of nitric oxide synthase (nNOS) can be useful in suspecting a dystrophinopathy with a mutation in the 'hot-spot' rod domain and help to direct molecular analysis. nNOS localizes to the sarcolemma of mature muscle fibres via several components of the dystrophin-associated protein complex (DAPC) including dystrophin but sarcolemmal nNOS is lost when dystrophin levels are very low or absent because of deletions in critical regions of the rod domain. We report three cases who presented with only mild or no muscle weakness but had elevated serum creatine kinase activity and dystrophin immunolabelling indistinguishable from normal, making a pathological diagnosis difficult. All three cases had a complete absence of sarcolemmal nNOS and were subsequently found to have an in-frame deletion in the common rod domain exons (in these cases 48, 45-51, 47-53) compatible with a BMD. In addition, we observed that nNOS appears to be developmentally regulated with the antibody used and was often absent from the sarcolemma of immature fibres. These findings demonstrate the value of including antibodies to nNOS in routine immunohistochemical studies and that absence of nNOS can be a more sensitive marker than up-regulation of utrophin for diagnosis of BMD. Immaturity of fibres, however, needs to be taken into account, especially in neonates.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15488030     DOI: 10.1111/j.1365-2990.2004.00561.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  23 in total

1.  Effects of Sildenafil on Cerebrovascular Reactivity in Patients with Becker Muscular Dystrophy.

Authors:  Ulrich Lindberg; Nanna Witting; Stine Lundgaard Jørgensen; John Vissing; Egill Rostrup; Henrik Bo Wiberg Larsson; Christina Kruuse
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

2.  Sodium nitrate alleviates functional muscle ischaemia in patients with Becker muscular dystrophy.

Authors:  Michael D Nelson; Ryan Rosenberry; Rita Barresi; Evgeny I Tsimerinov; Florian Rader; Xiu Tang; O'Neil Mason; Avery Schwartz; Thomas Stabler; Sarah Shidban; Neigena Mobaligh; Shomari Hogan; Robert Elashoff; Jason D Allen; Ronald G Victor
Journal:  J Physiol       Date:  2015-11-02       Impact factor: 5.182

3.  Nitrosative stress elicited by nNOSµ delocalization inhibits muscle force in dystrophin-null mice.

Authors:  Dejia Li; Yongping Yue; Yi Lai; Chady H Hakim; Dongsheng Duan
Journal:  J Pathol       Date:  2010-10-28       Impact factor: 7.996

4.  Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials.

Authors:  Karen Anthony; Sebahattin Cirak; Silvia Torelli; Giorgio Tasca; Lucy Feng; Virginia Arechavala-Gomeza; Annarita Armaroli; Michela Guglieri; Chiara S Straathof; Jan J Verschuuren; Annemieke Aartsma-Rus; Paula Helderman-van den Enden; Katherine Bushby; Volker Straub; Caroline Sewry; Alessandra Ferlini; Enzo Ricci; Jennifer E Morgan; Francesco Muntoni
Journal:  Brain       Date:  2011-11-18       Impact factor: 13.501

5.  Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy.

Authors:  Sebahattin Cirak; Lucy Feng; Karen Anthony; Virginia Arechavala-Gomeza; Silvia Torelli; Caroline Sewry; Jennifer E Morgan; Francesco Muntoni
Journal:  Mol Ther       Date:  2011-11-15       Impact factor: 11.454

6.  Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy.

Authors:  Yi Lai; Gail D Thomas; Yongping Yue; Hsiao T Yang; Dejia Li; Chun Long; Luke Judge; Brian Bostick; Jeffrey S Chamberlain; Ronald L Terjung; Dongsheng Duan
Journal:  J Clin Invest       Date:  2009-02-23       Impact factor: 14.808

Review 7.  Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy.

Authors:  David G Allen; Nicholas P Whitehead; Stanley C Froehner
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

Review 8.  Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification.

Authors:  Kristin Wilson; Crystal Faelan; Janet C Patterson-Kane; Daniel G Rudmann; Steven A Moore; Diane Frank; Jay Charleston; Jon Tinsley; G David Young; Anthony J Milici
Journal:  Toxicol Pathol       Date:  2017-10-03       Impact factor: 1.902

9.  Cardiac expression of a mini-dystrophin that normalizes skeletal muscle force only partially restores heart function in aged Mdx mice.

Authors:  Brian Bostick; Yongping Yue; Chun Long; Nate Marschalk; Deborah M Fine; Jing Chen; Dongsheng Duan
Journal:  Mol Ther       Date:  2008-12-09       Impact factor: 11.454

10.  α2 and α3 helices of dystrophin R16 and R17 frame a microdomain in the α1 helix of dystrophin R17 for neuronal NOS binding.

Authors:  Yi Lai; Junling Zhao; Yongping Yue; Dongsheng Duan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.